PulmCCM

Share this post
Predicing vancomycin failure in MRSA bacteremia
www.pulmccm.org

Predicing vancomycin failure in MRSA bacteremia

Apr 16, 2011
Share this post
Predicing vancomycin failure in MRSA bacteremia
www.pulmccm.org

Death, long hospital stays, and treatment failures are more likely when vancomycin is used for MRSA bacteremia with minimum inhibitory concentrations (MIC) > 1 mcg/mL. Lubin et al propose a clinical prediction rule to predict relative vancomycin resistance, based on a retrospective analysis of 272 patients with MRSA bacteremia at Tufts. Oversimplifying slightly: Having less than two risk factors (age > 50; prior receipt of vanco; prior MRSA bacteremia; chronic liver disease, or a nontunneled venous catheter) had a 91% negative predictive value for having an MRSA strain with MIC > 1 (relative vancomycin resistance). Having 2 or more factors had a positive predictive value of only 30%, though. There was no prospective validation cohort. Clin Infect Dis 2011;52:997-1002.

Share this post
Predicing vancomycin failure in MRSA bacteremia
www.pulmccm.org
Comments
TopNew

No posts

Ready for more?

© 2023 PulmCCM
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing